Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Prometheus Biosciences, Inc. (RXDX)

199.92   0.18 (0.09%) 06-15 16:00
Open: 199.68 Pre. Close: 199.74
High: 199.96 Low: 199.92
Volume: 1,787,021 Market Cap: 9,559(M)

Technical analysis

as of: 2023-07-07 4:48:28 PM
Short-term rate:       
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Mid-term rate:       
Target: Six months: 233.5     One year: 272.73
Support: Support1: 193.64    Support2: 189.75
Resistance: Resistance1: 199.91    Resistance2: 233.5
Pivot: 199.02
Moving Average: MA(5): 199.49     MA(20): 198.36
MA(100): 150.62     MA(250): 96
MACD: MACD(12,26): 3.9     Signal(9): 5
Stochastic oscillator: %K(14,3): 100     %D(3): 93.9
RSI: RSI(14): 84
52-week: High: 199.91  Low: 25.64
Average Vol(K): 3-Month: 1,223 (K)  10-Days: 833 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ RXDX ] has closed Bollinger Bands are 94.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 29 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 200.03 - 201.06 201.06 - 201.84
Low: 197.49 - 198.58 198.58 - 199.43
Close: 198.2 - 200.02 200.02 - 201.42

Company Description

Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR600, an anti-tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; PR1800, an anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California.

Headline News

Fri, 16 Jun 2023
Merck Completes Acquisition of Prometheus Biosciences, Inc. - Merck

Tue, 30 May 2023
Prometheus Biosciences Stock: 8.5% IRR, Closing In A Month (RXDX) - Seeking Alpha

Wed, 24 May 2023
RXDX Stock Alert: Halper Sadeh LLC Is Investigating Whether the ... - Business Wire

Thu, 18 May 2023
What Makes Prometheus Biosciences (RXDX) an Attractive Investment Choice? - Yahoo Finance

Tue, 09 May 2023
Prometheus Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Progress - Yahoo Finance

Sat, 29 Apr 2023
With 67% ownership, Prometheus Biosciences, Inc. (NASDAQ:RXDX) boasts of strong institutional backing - Yahoo Finance

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 48 (M)
% Held by Insiders 3.323e+007 (%)
% Held by Institutions 16.6 (%)
Shares Short 4,900 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -1.6161e+008
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -4
Return on Assets (ttm) 64.7
Return on Equity (ttm) -20.1
Qtrly Rev. Growth 4e+006
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth -3.6
Operating Cash Flow 0 (M)
Levered Free Cash Flow -133 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow -6.71

Stock Dividends

Dividend 0
Forward Dividend 4.68e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.